Evidence map›Paper›PMID 33151048›Full record

ArticleThe world journal of men's health2021

Oral Testofen, L-Citrulline, Resveratrol, and Caffeine Supplement Drink Improves Sexual Function in Men with Phosphodiesterase 5 Inhibitors: Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study.

Masato Shirai, Yuto Miyoshi, Taiki Ogasa, Miho Miyoshi, Keisuke Ishikawa, Ippei Hiramatsu, Yuka Uesaka, Taiji Nozaki, Taro Koyama, Akira Tsujimura

Open access · diamondAbstract read
In one paragraph

Article in The world journal of men's health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Masato ShiraiDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0002-2120-3611
Yuto MiyoshiDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0002-7071-2826
Taiki OgasaDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0001-8007-0794
Miho MiyoshiDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0003-3886-2506
Keisuke IshikawaDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0002-9552-1719
Ippei HiramatsuDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0003-1174-1560
Yuka UesakaDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0001-8977-4798
Taiji NozakiDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0003-1213-747X
Taro KoyamaD Clinic Tokyo Men's, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1941-9210
Akira TsujimuraDepartment of Urology, Juntendo University Urayasu Hospital, Chiba, Japan. atsujimu@juntendo.ac.jp.ORCID https://orcid.org/0000-0002-3821-5184
Juntendo University · JPJuntendo University Urayasu Hospital · JPMenninger Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSexuality is very important for men's health. Currently, phosphodiesterase type 5 inhibitors (PDE5i) remain the first-line therapy for erectile dysfunction, and no other oral drugs or drinks are approved and used clinically to treat male libido or orgasm dysfunction. In reference to a pharmaceutical dosage document, growing health consciousness is said to have boosted yearly sales of supplement drinks to more than 170 billion yen (1.58 billion US dollars) in Japan. We have created a supplement drink comprised of testofen, L-citrulline, resveratrol, and caffeine. We hypothesized that our supplement drink would be effective for men with sexual dysfunction, and especially libido dysfunction. MATERIALS AND

methodsIn this study, men with sexual dysfunction received a placebo drink for 14 days or our supplement drink (testofen, 600 mg/d; L-citrulline, 800 mg/d; resveratrol, 300 mg/d; and caffeine, 40 mg/d) for another 14 days separated by a 7-day washout period. Patients continued on-demand use of PDE5i. The International Index of Erectile Function (IIEF) score and adverse events were assessed.

resultsTwenty patients aged 30-7 years old were enrolled in and concluded the study with no adverse events experienced. The IIEF domains of desire frequency, erection frequency, erection firmness, erection confidence, intercourse satisfaction, ejaculation frequency, orgasm frequency, and overall satisfaction were significantly improved with our supplement drink.

conclusionsThis is the first study to show that our supplement drink may not only be effective for erection but also for libido, orgasm, and ejaculation.

Indexed as

CaffeineCitrullineResveratrolSexual dysfunction, physiologicalTrigonella

Identifiers

PMID33151048
PMCPMC8443991
OpenAlexW3097905279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.